Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HXHongyun Xing

Discussion

Loading...

Member takes

Overview

Observational analysis showed 75% objective response in patients with R/R DLBCL treated with zanubrutinib and chemotherapy, indicating potential benefit.

Key Points

  • Overall objective response rate was 75%, including a complete response rate of 33.3%.
  • Patients received an average of 4 treatment cycles of zanubrutinib combined with chemotherapy.
  • Zanubrutinib demonstrated efficacy in combination with R-CHOP and R-GemOx regimens among patients.
  • Adverse events included neutropenia in 58.3% and pulmonary infections in 45.8% of patients.

Cite This Study

Hongyun Xing (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2a3https://doi.org/10.1182/blood-2025-7218
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).2025
  2. 2Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma2025
  3. 3Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  4. 4Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  5. 5Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma2025 · 2 citations